SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here Piper Sandler 36th Annual Healthcare Conference in New York, NY on Wednesday, December 4, 2024 at 1:00 p.m. Eastern Time / 4:00 p.m. Pacific Time – webcast link hereThe p ...

SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home ...

- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today an ...

– Relapse-free/progression-free survival for NKTR-255 plus CD19-22 CAR-T cell therapy at 12 months was double that of historical controls (67% vs 38%) – – Eight of nine patients achieved complete remission, all without detectable MRD – SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targ ...

- New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis - SAN FRANCISCO, Sept. 25, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several presentations for rezpegaldesleukin (REZPEG) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress. In addition to two trial-in-progress posters, new proteomic analyses were pr ...

Investors might want to bet on Nektar Therapeutics (NKTR) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power o ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Vivian Wu - Associate Director, Investor Relations & Corporate Affairs Howard Robin - President, Chief Executive Officer & Director Jonathan Zalevsky - Chief Research & Development Officer Mary Tagliaferri - Chief Medical Officer Sandra Gardiner - Chief Financial Officer Conference Call Participants Jay Olson - Oppenheimer Kambiz Yazdi - Jefferies Andy Hsieh - William Blair Arthur He - H.C. Wain ...

Nektar Therapeutics (NKTR) incurred a loss per share of 25 cents in the second quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 21 cents. Excluding the impact of non-cash restructuring and impairment charges, the company reported an adjusted loss of 19 cents per share in the second quarter of 2024 compared with an adjusted loss of 18 cents per share in the year-ago quarter. Total revenues were $23.5 million in the second quarter, up 14.6% year over year. Revenues beat the Zack ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -19.05%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.18, delivering a surprise of 14.29%. Over the last four quarters, ...

Financial Performance - Total revenue for the three months ended June 30, 2024, was $23.489 million, a 15% increase compared to $20.499 million for the same period in 2023[98] - Product sales increased by 43% to $6.640 million in Q2 2024 from $4.658 million in Q2 2023[98] - The company reported a net loss of $52.363 million for the three months ended June 30, 2024, compared to a net loss of $51.122 million for the same period in 2023, reflecting a 2% increase in losses[98] - Product sales increased to $12,674 million for the six months ended June 30, 2024, representing a 35% increase compared to $9,376 million in the same period of 2023[100] - Total revenue for the six months ended June 30, 2024, was $45,128 million, a 7% increase from $42,093 million in 2023[100] - Net loss for the six months ended June 30, 2024, was $89,165 million, a 53% improvement compared to a net loss of $188,140 million in 2023[100] - Cash flows used in operating activities for the six months ended June 30, 2024, were $85.6 million, down from $103.4 million in the same period of 2023[120] Research and Development - Research and development expenses remained stable at $29.724 million in Q2 2024, compared to $29.681 million in Q2 2023[98] - Research and development expenses are expected to increase in 2024 due to the development of rezpegaldesleukin in two Phase 2b trials[105] - The company initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis in late October 2023[92] - Rezpegaldesleukin demonstrated dose-dependent improvements in eczema area and severity index (EASI) and was well tolerated in a Phase 1b study[92] - NKTR-255 is being evaluated in a Nektar-sponsored Phase 2 study following CD19 CAR-T cell therapy in patients with large B-cell lymphoma, with data expected before the end of 2024[94] - The company is advancing its preclinical program NKTR-0165, a TNF receptor type II agonist, with IND enabling studies planned for 2024[94] - The company plans to continue advancing promising early research drug candidates into preclinical development over the next several years[107] Expenses and Costs - Total operating costs and expenses decreased to $130,329 million for the six months ended June 30, 2024, down 43% from $227,402 million in 2023[100] - General and administrative expenses increased for the six months ended June 30, 2024, reflecting a reduction in facilities costs allocated to research and development[110] - The company incurred $5.5 million in costs for the wind down of the bempegaldesleukin program in 2023, with these costs reported within research and development expenses for 2024[112] - Severance and benefits expense for the 2023 Restructuring Plan totaled $7.9 million in 2023, with no expected expenses for this plan in 2024[112] - The company recognized $35.3 million in non-cash impairment charges for the full year 2023, primarily related to office and laboratory space[114] - The company recorded a provision of $3.1 million for net realizable value as of June 30, 2024, due to expected revenue being less than manufacturing costs[102] Cash and Investments - The company has approximately $290.6 million in cash and investments in marketable securities as of June 30, 2024, to fund its business plans for at least the next twelve months[96] - The company expects cash flows used in operating activities to increase in 2024 due to the development of rezpegaldesleukin in Phase 2b trials[120] - The company has no credit facility or committed capital sources, with financing alternatives dependent on the success of drug development programs[119] Collaborations and Agreements - The company received $1.9 billion in total consideration from collaboration agreements, including a $150 million upfront payment from Lilly for rezpegaldesleukin[119] - The company regained full rights to rezpegaldesleukin after the termination of the licensing agreement with Eli Lilly on April 23, 2023[92] - The company expects to significantly reduce the provision for net realizable value in the three months ending September 30, 2024, following a new agreement with UCB[102] - Non-cash royalty revenue is expected to decrease for the full year 2024 due to a reduction in royalty rates from UCB[103] - The company is seeking to sublease all laboratory and office space due to adverse market conditions, particularly in the San Francisco Bay Area[119]